BMY Draws Investor Focus After Bayer Reports Promising FXIa Trial Results
After Bayer announced promising FXIa inhibitor trial results, investors are reassessing the anticoagulant landscape - putting Bristol Myers Squibb (BMY) and Eliquis in focus for competitive impact.
Yahoo Finance
2 min read
Stocks
Market Analysis
Pharmaceuticals